KRAS and esophageal squamous cell carcinoma: It is reported that STK11-activated autophagy enhances resistance to the combination of trametinib and radiation in KRAS-mutant NSCLC and promotes esophageal squamous cell carcinoma cell survival after radiation (62, 63).